In mechanically ventilated patients with airway obstruction, helium-oxygen (He-O2) mixtures reduce airway resistance and improve ventilation, but their influence on aerosol delivery is unknown. Accordingly, we determined the effect of various He-O2 mixtures on albuterol delivery from metered-dose inhalers (MDIs) and jet nebulizers in an in vitro model of mechanical ventilation. Albuterol delivery from a MDI was increased when the ventilator circuit contained 80% helium and 20% oxygen (He-O2 80/20) versus O2: 46.7 +/- 3.3 versus 30.2 +/- 1.3 (SE)% of the nominal dose (p < 0.001)-the difference was mainly due to decreased drug deposition in the spacer chamber, mean 39.2% and 55.2%, respectively (p < 0.001). Nebulizer efficiency at a flow rate of 6 L/min was five times lower with He-O2 80/20 than O2, and the amount of nebulized drug was inversely correlated with gas density (r = 0.94, p < 0.0001). When the nebulizer was operated with O2, greater albuterol delivery was achieved when the ventilator circuit contained He-O2 rather than O2. In summary, He-O2 mixtures in the circuit increased aerosol delivery for both MDIs and nebulizers in the mechanically ventilated model by as much as 50%. In conclusion, at appropriate flow rates and concentrations, He-O2 in the ventilator circuit may improve aerosol delivery in mechanically ventilated patients with severe airway obstruction.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1164/ajrccm.163.1.2003025 | DOI Listing |
Nat Commun
January 2025
Aiiso Yufeng Li Family Department of Chemical and Nano Engineering, University of California San Diego, La Jolla, CA, USA.
Amidst the rising prevalence of respiratory diseases, the importance of effective lung treatment modalities is more critical than ever. However, current drug delivery systems face significant limitations that impede their efficacy and therapeutic outcome. Biohybrid microrobots have shown considerable promise for active in vivo drug delivery, especially for pulmonary applications via intratracheal routes.
View Article and Find Full Text PDFACS Nano
January 2025
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
Inhalation delivery, offering a direct pathway for administering drugs to the lungs in the form of dry powders or aerosols, stands out as an optimal approach for the localized treatment of pulmonary diseases. However, the intricate anatomical architecture of the lung often poses challenges in maintaining effective drug concentrations within the lungs over extended periods. This highlights the pressing need to develop rational inhalable drug delivery systems that can improve treatment outcomes for respiratory diseases.
View Article and Find Full Text PDFInt J Pharm
January 2025
HUN-REN Centre for Energy Research, Konkoly Thege M. út, 29-33, 1121 Budapest, Hungary. Electronic address:
In the majority of aerosol drug deposition modelling efforts, the particles are approximated by regular spheres. However, microscope images acquired after drug formulation available in the open literature suggest that their shape is not regular in most cases. This work aimed to combine experimental measurements and numerical simulations to reveal the shape factors of the particles of commercialized aerosol drugs and the effect of non-sphericity on the lung deposition distribution of these drugs.
View Article and Find Full Text PDFJ Aerosol Med Pulm Drug Deliv
January 2025
Department of Mechanical Engineering, University of Alberta, Edmonton, Canada.
Dry powders offer the potential to increase stability and reduce cold-chain requirements associated with the distribution of vaccines and other thermally sensitive products. The Alberta Idealized Nasal Inlet (AINI) is a representative geometry for characterization of nasal products that may prove useful in examining intranasal delivery of powders. Spray-dried trehalose powders were loaded at 10, 20, and 40 mg doses into active single-dose devices.
View Article and Find Full Text PDFJ Control Release
January 2025
Univ Brest, Inserm, EFS, UMR 1078, GGB, F-29200, Brest, France; CHU de Brest, Service de Génétique Médicale et de Biologie de la Reproduction, F-29200 Brest, France. Electronic address:
Aerosol delivery represents a rapid and non-invasive way to directly reach the lungs while escaping the hepatic first-pass effect. The development of pulmonary drugs for respiratory diseases such as cystic fibrosis, lung infections, pulmonary fibrosis or lung cancer requires an enhanced understanding of the relationships between the natural physiology of the respiratory system and the pathophysiology of these conditions. This knowledge is crucial to better predict and thereby control drug deposition.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!